Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195378 | 1.00 | CYP2C9 (0.35) | CYP2C9CYP3A4CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL5921131 | 0.97 | CYP2C9 (0.35) | CYP2C9CYP3A4CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL5921128 | 0.97 | CYP2C9 (0.35) | CYP2C9CYP3A4CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL5677476 | 0.96 | CYP3A4 (0.36) | CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL5677480 | 0.96 | CYP3A4 (0.36) | CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL5680691 | 0.96 | CYP2C9 (0.35) | CYP2C9CYP3A4CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL5680688 | 0.96 | CYP2C9 (0.35) | CYP2C9CYP3A4CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL5681098 | 0.95 | CYP3A4 (0.32) | CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL5681101 | 0.95 | CYP3A4 (0.32) | CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL5920722 | 0.95 | CYP3A4 (0.37) | CYP2C9CYP3A4CYP2D6CYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620447-B1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEM PATENTS INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | CYP2C9 3740/4885CYP3A4 1091/4885CYP2D6 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.